TP53 and thyroid gland carcinoma: The results demonstrate that IMCA is an anticancer drug candidate for thyroid carcinoma chemotherapy and may work as a specific antagonist of NR4A1 through the nuclear export of NR4A1 and the p53-sestrins-AMPK-mTOR signaling pathway.